Invokana (canagliflozin) is used to treat type 2 diabetes and is part of the drug class referred to as SGLT2. SGLT2, or sodium/glucose cotransporter 2, is sodium-dependent glucose transport protein. Invokana was developed by Mitsubishi Tanabe Pharma, and is now produced by Jansen Pharmaceuticals, a subdivision of Johnson & Johnson. The drug was FDA approved in March of 2013 for treatment of type 2 diabetes. However, SGLT2 inhibitor medications, like Invokana, have been linked to a higher-than-normal development of ketoacidosis, a life-threatening condition.
What is Ketoacidosis?
Ketoacidosis is a serious medical condition that can lead to a coma or even death. It occurs when the body produces too many ketones, an acid that breaks down fat in the body. This happens when your cells to do not get enough glucose for energy and must burn fat in order to get an energy source. Some warning symptoms of ketoacidosis include:
- Difficulty breathing
- Confusion, dizziness, or fainting
- Abdominal pain
Have I Been Affected?
If you or someone you know has developed ketoacidosis after taking Invokana, or someone you know has died in associated with treatment by Invokana, please contact us right away for a free confidential evaluation.